Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Disease Relapse by Monitoring Circulating Cancer DNA After Chemotherapy in Patients With MDS and AML

NCT03138395 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT03138395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03138395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Disease Relapse by Monitoring Circulating Cancer DNA After Chemotherapy in Patients With MDS and AML
Lead sponsor
University of Florida
Phase
Observational
Overall status
Withdrawn
Start date
September 15, 2017
Completion date
August 15, 2019
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia, aml, mds, myelodysplastic syndromes